A proteinogenic amino acid derivative resulting from reaction of L-tyrosine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tyrosine by a heteroatom.
ChEBI ID: 27177
| Member | Definition | Role |
|---|---|---|
| 2-s-cysteinyldopa | An L-tyrosine derivative that is L-DOPA in which the hydrogen at position 2 on the phenyl ring is replaced by a cysteinyl group. Found in the urine of patients with melanoma. | 2-S-cysteinyl-DOPA |
| 3-chloro-L-tyrosine | A chloroamino acid comprising a tyrosine core with a chloro- substituent ortho to the phenolic hydroxy group. | 3-chloro-L-tyrosine zwitterion; 3-chloro-L-tyrosine |
| 3-methoxytyrosine | A L-tyrosine derivative that is the 3-methoxy derivative of L-dopa. | 3-O-methyldopa zwitterion; 3-O-methyldopa |
| benzoyltyrosine ethyl ester | An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine. | ethyl N-benzoyl-L-tyrosinate |
| diiodotyrosine | A diiodotyrosine that is L-tyrosine carrying iodo-substituents at positions C-3 and C-5 of the benzyl group. It is an intermediate in the thyroid hormone synthesis. | 3,5-diiodo-L-tyrosine |
| droxidopa | A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension | droxidopa |
| ethyl n-alpha-acetyl-tyrosinate | An L-tyrosine derivative that is the ethyl ester of N-acetyltyrosine. | ethyl N-acetyl-L-tyrosinate |
| levodopa | An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease | L-dopa zwitterion; L-dopa |
| lysine tyrosylquinone | An L-lysine derivative in which one of the amino hydrogens at N(6)-amino is substituted by a 6-[(2S)-2-amino-2-carboxyethyl]-3,4-dioxocyclohexa-1,5-dien-1-yl group. | 5'-(N(6)-L-lysine)-L-tyrosylquinone |
| methyl-3-tyrosine | A tyrosine derivative that is L-tyrosine in which the hydrogen at position 3 on the phenyl ring is replaced by a methyl group. | 3-methyl-L-tyrosine zwitterion; 3-methyl-L-tyrosine |
| methyldopa | A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring. | alpha-methyl-L-dopa |
| metyrosine | An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. | alpha-methyl-L-tyrosine |
| monoiodotyrosine | The monoiodotyrosine that is L-tyrosine carrying an iodo-substituent at position C-3 of the benzyl group. | 3-iodo-L-tyrosine zwitterion; 3-iodo-L-tyrosine |
| n-hydroxytyrosine | An L-tyrosine derivative obtained by replacement of one of the amino hydrogen by a hydroxy group. | N-hydroxytyrosine |
| phosphotyrosine | A non-proteinogenic L-alpha-amino acid that is L-tyrosine phosphorylated at the phenolic hydroxy group. | O(4)-phospho-L-tyrosine |
| tirofiban | A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. | tirofiban |
| tyrosinamide | An amino acid amide that is L-tyrosine in which the carboxy OH group is replaced by NH2. | L-tyrosinamide |
| tyrosine o-sulfate | An O-sulfoamino acid that is L-tyrosine in which the phenolic hydrogen has been replaced by a sulfo group. | O(4')-sulfo-L-tyrosine |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9,038 (30.58) | 18.7374 |
| 1990's | 6,802 (23.02) | 18.2507 |
| 2000's | 6,632 (22.44) | 29.6817 |
| 2010's | 5,303 (17.94) | 24.3611 |
| 2020's | 1,779 (6.02) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 2,677 (8.46%) | 5.53% |
| Reviews | 3,078 (9.73%) | 6.00% |
| Case Studies | 2,338 (7.39%) | 4.05% |
| Observational | 108 (0.34%) | 0.25% |
| Other | 23,436 (74.08%) | 84.16% |